<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30981" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Varicella (Chickenpox) Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kota</surname>
            <given-names>Vasudha</given-names>
          </name>
          <aff>University of Michigan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Grella</surname>
            <given-names>Marc J.</given-names>
          </name>
          <aff>Harvard Medical School</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vasudha Kota declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marc Grella declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30981.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Varicella-zoster virus (chickenpox) is an acute febrile rash illness that was very common in children in the United States before the universal vaccination program existed. Luckily, the varicella-zoster virus is a vaccine-preventable disease. The FDA approves using the live varicella virus vaccine to provide immunity for preventing varicella in individuals 12 months older. This activity reviews the mechanism of action, indications, contraindications, adverse effects of this vaccine, and the front-line personnel involved in preventing the disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the goals of vaccination with the varicella vaccine.</p></list-item><list-item><p>Evaluate&#x000a0;the mechanism of action of the varicella vaccine.</p></list-item><list-item><p>Assess&#x000a0;the potential adverse reactions expected following vaccination with the varicella vaccine.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination to advance varicella vaccination and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30981&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30981">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30981.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Varicella or chickenpox is a common and highly contagious exanthematic disease caused by the varicella-zoster virus that, during primary infection, can establish latency.&#x000a0;Varicella-zoster virus&#x000a0;reactivation, even decades after primary infection, causes&#x000a0;herpes zoster. Varicella&#x000a0;still represents the most widespread vaccine-preventable childhood infectious disease in industrialized countries; due to its relevant burden on healthcare resources, several countries have introduced&#x000a0;varicella&#x000a0;vaccination into the recommended routine childhood national immunization schedule.<xref ref-type="bibr" rid="article-30981.r1">[1]</xref>&#x000a0;</p>
        <p>Varicella-zoster virus (chickenpox)&#x000a0; was very&#x000a0;common in children in the United States before the universal vaccination program existed.<xref ref-type="bibr" rid="article-30981.r2">[2]</xref>&#x000a0;The varicella-zoster virus manifestations are usually very&#x000a0;mild and self-limited, but in young infants and adults, the complications can be life-threatening. Luckily,&#x000a0;the varicella-zoster virus&#x000a0;is a vaccine-preventable disease, and the FDA approves the live varicella virus vaccine to provide immunity for preventing varicella in individuals 12 months and older. Current vaccines against&#x000a0;varicella and&#x000a0;herpes zoster are not 100% efficacious; it&#x000a0;is between 70%&#x000a0;and 90% effective&#x000a0;at preventing varicella and&#x000a0;over 95% effective&#x000a0;at preventing severe varicella.<xref ref-type="bibr" rid="article-30981.r3">[3]</xref> Specifically, studies have shown that&#x000a0;1 dose of varicella vaccine can lead to breakthrough&#x000a0;varicella, albeit rarely, in children, and a 2-dose regimen is now recommended.<xref ref-type="bibr" rid="article-30981.r4">[4]</xref> The varicella vaccine is used routinely in children with&#x000a0;2 doses.</p>
        <p>The first dose is given&#x000a0;to children between 12 to 15 months of age, and the administration of the second dose is for children between 4 to 6 years old.<xref ref-type="bibr" rid="article-30981.r5">[5]</xref><xref ref-type="bibr" rid="article-30981.r6">[6]</xref>&#x000a0;If&#x000a0;3 months have passed since the first dose, one may opt to give the second dose earlier. If a child has never been vaccinated or had chickenpox, the practitioner should give the&#x000a0;2 doses at least 28 days apart. One may give the varicella vaccine at the same time as other vaccines; however, evidence demonstrates an increase in the breakthrough disease when the varicella vaccine administration is within&#x000a0;4 weeks of the measles-mumps-rubella (MMR) vaccine. The recommendation is to give the vaccines&#x000a0;simultaneously in different injection sites or&#x000a0;4 weeks apart. A quadrivalent combination vaccine called MMRV, which consists of MMR and varicella, may be provided in place&#x000a0;of the&#x000a0;2 individual doses if the child is younger than 12 years old. The FDA has not approved the use of this vaccine in pregnancy, and intense immune status evaluation is required in individuals with a family history of congenital immunodeficiencies.<xref ref-type="bibr" rid="article-30981.r7">[7]</xref><xref ref-type="bibr" rid="article-30981.r8">[8]</xref>&#x000a0;</p>
        <p>The varicella vaccine is now FDA-approved to give&#x000a0;for post-exposure use and outbreak control. The vaccine should be given as soon as possible after exposure, but it has shown effectiveness in preventing or modifying disease within&#x000a0;3 to&#x000a0;5 days post-exposure.<xref ref-type="bibr" rid="article-30981.r9">[9]</xref> Oral acyclovir administered during the virus's incubation period may also modify varicella disease in a healthy child. However, this practice has not yet been FDA-approved and needs further evaluation. A high-titer anti-varicella virus immune globulin can also be used as&#x000a0;prophylaxis in immunocompromised children, pregnant women, and newborns exposed to varicella. Another indication for prophylaxis with the immune globulin is in close contact with a high-risk susceptible individual and someone who has herpes zoster.<xref ref-type="bibr" rid="article-30981.r10">[10]</xref><xref ref-type="bibr" rid="article-30981.r11">[11]</xref></p>
        <p>You can demonstrate evidence of immunity to varicella by showing documentation. The following&#x000a0;topic proves age-appropriate vaccination with varicella vaccine:</p>
        <list list-type="bullet">
          <list-item>
            <p>Preschool-age children (older than 12 months):&#x000a0;1 dose</p>
          </list-item>
          <list-item>
            <p>School-age children, adolescents, and adults:&#x000a0;2 doses</p>
          </list-item>
          <list-item>
            <p>Laboratory evidence or confirmation of the disease</p>
          </list-item>
          <list-item>
            <p>Birth in the United States before 1980; unless one is immunocompromised, a pregnant woman, or a health care worker (born before 1980 does not count as evidence of immunity in this population)</p>
          </list-item>
          <list-item>
            <p>Diagnosis or verification of a history of varicella disease by a healthcare provider</p>
          </list-item>
          <list-item>
            <p>Diagnosis or verification of a history of herpes zoster by a healthcare provider</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30981.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The varicella-zoster vaccine contains live attenuated varicella-zoster vaccine&#x000a0;(Oka strain). This vaccine induces both humoral and cell-mediated immune responses. It produces an IgG humoral immune response in individuals, and the cell-mediated immune response is caused by varicella-zoster-specific activation of both CD4+ T-helper and CD8+ T-lymphocyte cells. The protection duration is still unknown; however, some efficacy trials have shown that the vaccine can offer continued protection for up to&#x000a0;10 years after vaccination.&#x000a0;</p>
      </sec>
      <sec id="article-30981.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The varicella vaccine is only available to be administered subcutaneously. Practitioners should inject the vaccine in the upper arm's outer aspect, deltoid region, or anterolateral thigh. For adult immunization, the vaccine is administered subcutaneously as 0.5 mL in 2 doses 4 to 8 weeks apart.</p>
        <p>
<bold>Pediatric Immunization</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>From 12 months to 12 years: 0.5 mL subcutaneously for&#x000a0;1 dose between 12 to 15 months, then 0.5 mL subcutaneously between the ages of 4 and 6.</p>
          </list-item>
          <list-item>
            <p>If ages 7 to 12 at series start, the second dose may be administered as soon as&#x000a0;4 weeks after the initial dose.</p>
          </list-item>
          <list-item>
            <p>If ages 13 and older at the series start, the vaccine is administered 0.5 mL subcutaneously for 2 doses 4 to 8 weeks apart.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30981.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The Varicella vaccine is safe and well-tolerated. According to some sources, injection site complaints after vaccination were slightly higher after the second dose than the first. The most commonly reported adverse effect is soreness or swelling at the injection site. Some other mild reported reactions&#x000a0;include fever and mild vaccine-associated varicelliform rash. The rash comprises&#x000a0;6 to&#x000a0;10 papular, vesicular, erythematous lesions that peak 8 to 21 days after injection. It is&#x000a0;rare, but other household members are susceptible to transmission when an individual has this rash after getting the vaccine. Some of the moderate&#x000a0;reported reactions include a fever that causes a low-grade seizure (showing jerking or staring), but this is rare and more frequently reported with the MMRV vaccine&#x000a0;5 to 12 days after the vaccine, and upper&#x000a0;respiratory infection, which can include a cough, chest pain, and difficulty breathing. Serious&#x000a0;reported reactions include pneumonia, low blood cell count, and severe brain reactions. These are all extremely&#x000a0;rare, and researchers still do not understand if the vaccine causes these reactions. After the vaccine is administered, it is recommended that salicylates be avoided for&#x000a0;5 weeks due to the risk of Reyes syndrome and that contact with susceptible high-risk individuals be avoided.</p>
      </sec>
      <sec id="article-30981.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The varicella vaccine is contraindicated in individuals who have a severe allergy or have had an&#x000a0;anaphylactic reaction to neomycin or gelatin, which are components of this vaccine, or to the previous dose of a varicella-containing vaccine.<xref ref-type="bibr" rid="article-30981.r12">[12]</xref><xref ref-type="bibr" rid="article-30981.r13">[13]</xref>&#x000a0;It is also contraindicated in individuals who are immunosuppressed or immunodeficient in any of the following ways:</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe combined immunodeficiency, lymphoma, leukemia, AIDS, blood dyscrasias, hypogammaglobulinemia, agammaglobulinemia, IgA deficiency, malignant neoplasms affecting the bone marrow or lymphatic system, patients receiving steroids, chemotherapy, or X-rays as&#x000a0;a treatment for cancer&#x000a0;or X-rays</p>
          </list-item>
          <list-item>
            <p>Any patient showing clinical signs of infection with HIV</p>
          </list-item>
          <list-item>
            <p>Any person who has a family history of congenital or hereditary immunodeficiency in first-degree relatives unless there is demonstrable immunocompetence of the potential vaccine recipient</p>
          </list-item>
        </list>
        <p>Patients can not receive the vaccine if they present with febrile illness or have active, untreated tuberculosis. Vaccination is contraindicated in pregnant females, and women should delay pregnancy for&#x000a0;3 months after vaccination by using effective birth control. Maternal varicella infection has been shown to harm the fetus, but the vaccination effects have not been tested on pregnant women, and the effects on fetal development are currently unknown. It is also not known whether the varicella vaccine virus passes in breast milk, and it is best to avoid vaccination during&#x000a0;breastfeeding&#x000a0;for that reason. There&#x000a0;is currently&#x000a0;no clinical data available on the efficacy or the safety of administration of the varicella vaccine in children younger than 12 months old.</p>
      </sec>
      <sec id="article-30981.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>No routine tests are recommended in conjunction with this vaccine.</p>
      </sec>
      <sec id="article-30981.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All interprofessional healthcare team members, including&#x000a0;clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists, are frontline professionals&#x000a0;in preventing chickenpox. Because of the anti-vaccination sentiment in society, healthcare professionals must educate the public on the importance of vaccination.<xref ref-type="bibr" rid="article-30981.r11">[11]</xref> For children who develop an infection, the parents should receive education on trimming the child's fingernails to minimize excoriation marks and bacterial&#x000a0;superinfections. The pharmacist should warn the parents not to administer aspirin to young children with fever&#x000a0;because of the risk of Reye syndrome. All pregnant women who develop chickenpox should obtain a referral to an infectious disease specialist regarding treatment. Further, postpartum women with chickenpox should be encouraged to breastfeed if they desire because it is safe.<xref ref-type="bibr" rid="article-30981.r14">[14]</xref><xref ref-type="bibr" rid="article-30981.r15">[15]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Chickenpox in a healthy individual is a self-limiting illness with an excellent outcome. However, in immunocompromised individuals, the infection can be associated with very high morbidity and mortality. The currently&#x000a0;available Varicella vaccine is safe and well-tolerated. According to some sources, injection site complaints after vaccination were slightly higher after the second dose than the first. The most commonly reported adverse effect is soreness or swelling at the injection site.<xref ref-type="bibr" rid="article-30981.r16">[16]</xref><xref ref-type="bibr" rid="article-30981.r17">[17]</xref></p>
        <p>Varicella/herpes zoster vaccines require the collaboration of the entire interprofessional healthcare team. In many states, pharmacists are empowered to administer the vaccine in the pharmacy, and they must let the patient's physician know so records can be updated appropriately. Physicians, nurses, and pharmacists are all responsible for patient counseling and ensuring the patient is a viable vaccine candidate, in line with the abovementioned restrictions. Should they encounter any of these contraindications, they must communicate them to the entire healthcare team so all members are on the same page and patient records can be updated. This interprofessional approach ensures maximal effectiveness for varicella/herpes zoster vaccination strategies.</p>
      </sec>
      <sec id="article-30981.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30981&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30981">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30981/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30981">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30981.s10">
        <title>References</title>
        <ref id="article-30981.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabutti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maniscalco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stefanati</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs.</article-title>
            <source>Minerva Pediatr</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>68</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-25</page-range>
            <pub-id pub-id-type="pmid">27125440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ong</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Vasanwala</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Baikunje</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Varicella infections in patients with end stage renal disease: a systematic review.</article-title>
            <source>BMC Nephrol</source>
            <year>2018</year>
            <month>Jul</month>
            <day>24</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>185</fpage>
            <pub-id pub-id-type="pmid">30041621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <collab>American Academy of Pediatrics Committee on Infectious Diseases</collab>
            <article-title>Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule.</article-title>
            <source>Pediatrics</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>221</fpage>
            <page-range>221-31</page-range>
            <pub-id pub-id-type="pmid">17606582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haberthur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Engelmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Legasse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dewane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Messaoudi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection.</article-title>
            <source>PLoS Pathog</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>e1002367</fpage>
            <pub-id pub-id-type="pmid">22102814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Elam-Evans</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Yankey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mbaeyi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Fredua</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stokley</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>24</day>
            <volume>67</volume>
            <issue>33</issue>
            <fpage>909</fpage>
            <page-range>909-917</page-range>
            <pub-id pub-id-type="pmid">30138305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gray</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cathie</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Fifteen-minute consultation: Chickenpox vaccine-should parents immunise their children privately?</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>120</fpage>
            <page-range>120-123</page-range>
            <pub-id pub-id-type="pmid">30077987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lo Presti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Curti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bornet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vanelle</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Chickenpox: An update.</article-title>
            <source>Med Mal Infect</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">29789159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>DYW</given-names>
              </name>
              <name>
                <surname>Edmunds</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>YCK</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>van Hoek</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Flasche</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The changing epidemiology of varicella and herpes zoster in Hong Kong before universal varicella vaccination in 2014.</article-title>
            <source>Epidemiol Infect</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>146</volume>
            <issue>6</issue>
            <fpage>723</fpage>
            <page-range>723-734</page-range>
            <pub-id pub-id-type="pmid">29526171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>Varicella and herpes zoster vaccines: WHO position paper, June 2014--Recommendations.</article-title>
            <source>Vaccine</source>
            <year>2016</year>
            <month>Jan</month>
            <day>04</day>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-199</page-range>
            <pub-id pub-id-type="pmid">26723191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marcellin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Vaccination in the early post-partum: Guidelines].</article-title>
            <source>J Gynecol Obstet Biol Reprod (Paris)</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>10</issue>
            <fpage>1135</fpage>
            <page-range>1135-40</page-range>
            <pub-id pub-id-type="pmid">26518154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baracco</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Eisert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saavedra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ortega-Sanchez</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Clinical and economic impact of various strategies for varicella immunity screening and vaccination of health care personnel.</article-title>
            <source>Am J Infect Control</source>
            <year>2015</year>
            <month>Oct</month>
            <day>01</day>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>1053</fpage>
            <page-range>1053-60</page-range>
            <pub-id pub-id-type="pmid">26138999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malaiya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Leventis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Varicella vaccination in the immunocompromised.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>567</fpage>
            <page-range>567-9</page-range>
            <pub-id pub-id-type="pmid">24758889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolan</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Lindley</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Strikas</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Vaccination policies among health professional schools: evidence of immunity and allowance of vaccination exemptions.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>186</fpage>
            <page-range>186-91</page-range>
            <pub-id pub-id-type="pmid">25633001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>Updated recommendations for use of VariZIG--United States, 2013.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2013</year>
            <month>Jul</month>
            <day>19</day>
            <volume>62</volume>
            <issue>28</issue>
            <fpage>574</fpage>
            <page-range>574-6</page-range>
            <pub-id pub-id-type="pmid">23863705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopez</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cardemil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cullen</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bialek</surname>
                <given-names>SR</given-names>
              </name>
              <collab>Division of Viral Diseases</collab>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Two-dose varicella vaccination coverage among children aged 7 years--six sentinel sites, United States, 2006-2012.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2014</year>
            <month>Feb</month>
            <day>28</day>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>174</fpage>
            <page-range>174-7</page-range>
            <pub-id pub-id-type="pmid">24572613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ackerson</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Sy</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Cheetham</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Association of the use of MMRV in infants by pediatric infectious disease specialists with that of other affiliated providers.</article-title>
            <source>Vaccine</source>
            <year>2014</year>
            <month>Apr</month>
            <day>01</day>
            <volume>32</volume>
            <issue>16</issue>
            <fpage>1863</fpage>
            <page-range>1863-8</page-range>
            <pub-id pub-id-type="pmid">24508041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30981.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szucs</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Pfeil</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of the cost effectiveness of herpes zoster vaccination.</article-title>
            <source>Pharmacoeconomics</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-36</page-range>
            <pub-id pub-id-type="pmid">23335045</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
